Despite a cautious capital environment, North American biotech companies secured nearly $2 billion in funding in January 2025, with …
Despite a cautious capital environment, North American biotech companies secured nearly $2 billion in funding in January 2025, with …
A new survey finds that over 80% of healthcare professionals notice sex-related differences in disease progression and treatment …
At the 2025 ASCO Gastrointestinal Cancers Symposium, ALX Oncology presents promising Phase II data showing that evorpacept, a …
Oncolytics Biotech discloses compelling new pelareorep combination data—in anal and pancreatic cancer cohorts—highlighting durable responses and tolerable safety …
Dogwood kicks off the Phase IIb study of Halneuron®, a non-opioid Nav1.7 inhibitor for chemotherapy-induced neuropathy—marking a critical …
The journal Nature identifies seven transformative technologies for 2025, with self-driving laboratories and advanced immunotherapies set to accelerate …
The European Medicines Agency approves GSK’s PD-1 inhibitor, Jemperli, in combination with chemotherapy as a first-line therapy for …
Arrowhead Pharmaceuticals’ NDA for plozasiran in rare, life-threatening FCS wins FDA acceptance, setting a PDUFA action date and …
Daiichi Sankyo’s antibody–drug conjugate Datopotamab Deruxtecan secures U.S. approval, offering a new treatment for patients with previously treated …
Evaxion Biotech reaches a key milestone in melanoma research as all patients complete dosing in its AI-driven personalized …